Background Endoscopic ultrasound (EUS)-guided drainage is widely used to manage pancreatic pseudocysts. Several studies have reported the use of EUS-guided drainage for pancreatic fistula and stasis of pancreatic juice caused by stricture of the pancreatic duct after pancreatic resection. Methods At the authors' hospital, 262 patients underwent surgery involving pancreatic resection from April 2005 to March 2010. In 90 of these patients (34%), a grade B or C postoperative pancreatic fistula developed that required additional treatment. The authors performed EUS-guided transmural drainage (EUS-TD) for six patients (2.1%) with a pancreatic fistula or dilation of the main pancreatic duct visible by EUS. Percutaneous drainage was provided for 18 patients (6.8%). The success rates for EUS-TD and percutaneous drainage were compared in a retrospective analysis. Results In all six cases, EUS-TD was performed successfully without complications. Five of the six patients were successfully treated with only one trial of EUS-TD. The final technical success rate was 100% for both EUS-TD and percutaneous drainage. Both the short-and longterm clinical success rates for EUS-TD were 100% and those for percutaneous drainage were 61.1 and 83%, respectively. The differences in these rates were not significant (short-term success, P = 0.091 vs. long-term success, P = 0.403). However, the time to clinical success was significantly shorter with EUS-TD (5.8 days) than with percutaneous drainage (30.4 days; P = 0.0013) in the current series. Conclusions The EUS-TD approach appears to be a safe and technically feasible alternative to percutaneous drainage and may be considered as first-line therapy for pancreatic fistulas visible by EUS.
Society of Hepato-Biliary-Pancreatic Surgery reported the rate of POPF after PD to be 30.2% [1] . Even with recent advances in pancreatic surgery, POPF remains the major contributor to morbidity after pancreatic resection.
The treatment of choice for POPF is external or internal drainage of pancreatic juice, which can be accomplished by surgical drainage, image-guided percutaneous drainage, or endoscopic drainage. A surgical cyst-enteric anastomosis has traditionally been performed, with high morbidity rates ranging from 7 to 37% [2, 3] . Percutaneous drainage offers satisfying results but requires a long therapy period (several weeks to months) due to the indwelling catheter and occasionally is associated with the formation of an external fistula [4, 5] . Furthermore, cutaneopancreatic fistulas that form after percutaneous drainage usually are intractable.
Endoscopic drainage has been performed increasingly during the last 10 years [6] [7] [8] . Two approaches have been used for endoscopic access: through the gastrointestinal wall by creation of a cystogastrostomy/cystoduodenostomy (transmural drainage) or via the papilla (transpapillary drainage). Both approaches, which usually require the insertion of one or more plastic stents [9] , have success rates of 70-87% and complication rates of 11-34% [10, 11] .
Recently, endoscopic ultrasound (EUS)-guided transmural drainage (EUS-TD) has been widely used to manage pancreatic pseudocysts, and its applications have been extended gradually with the development of more innovative techniques and devices. Several reports have indicated the feasibility of EUS-guided drainage of pancreatic fistulas and stasis of pancreatic juice caused by a pancreatic duct stricture after pancreatic resection [12, 13] . However, no detailed reports comparing EUS-TD and percutaneous drainage of a pancreatic fistula after pancreatic resection are available.
To examine the utility and efficacy of EUS-TD, we report six consecutive successful pancreatic fistula and pancreatic duct dilation cases managed by EUS-TD through the gastrointestinal tract and compare the outcomes with those of cases treated by conventional percutaneous drainage.
Patients and Methods
At our hospital, 262 patients underwent surgery involving pancreatic resection from April 2005 to March 2010. Of these patients, 172 (65%) did not have POPF and did not undergo additional treatment. The remaining 90 patients (34%) experienced POPF and required additional interventional treatment because they had symptoms such as fever and abdominal pain. Of these 90 patients, 66 were cured by conservative therapies, whereas 24 have not been cured since a convex array echo endoscope was introduced to our institution in April 2006.
When POPFs were visible by EUS, EUS-TD was the first choice for their treatment. Percutaneous drainage was the second choice for the treatment of refractory POPFs with symptoms and those not visible by EUS. As a result, POPFs in five patients (2.1%) and dilation of the main pancreatic duct (MPD) caused by a stricture of the anastomosis in one patient were detected by EUS and treated by EUS-TD. Patients with a POPF not visible by EUS were treated with percutaneous drainage (18 cases, 6.8%) or with a surgical drain followed by primary surgery (66 cases, 25%) for the aforementioned duration.
For the six patients treated with EUS-TD (Table 1) , the initial surgical indications were pancreatic carcinoma (PC) in three patients, bile duct carcinoma (BDC) in two patients, and ampullary carcinoma (AC) in one patient. Pancreatoduodenectomy had been performed in three cases, hepatopancreatoduodenectomy in two cases, and distal pancreatectomy (DP) in one case. A POPF developed in five patients (cases 1-5) after surgery, and dilation of the MPD developed in one case (case 6). Three patients (cases 1, 2, and 6) experienced fever, abdominal pain, or general fatigue as signs of a pancreatic fistula infection or stasis of pancreatic juice.
Of the 18 POPF patients treated with percutaneous drainage (Table 1) , seven with a clinical diagnosis of BDC, three with PC, two with intraductal papillary mucinous neoplasm (IPMN), and one each with AC, gallbladder cancer (GBC), and mucinous cystic neoplasm (MCN) had initially undergone PD or DP. Hepatopancreatoduodenectomy had been performed for three patients with a diagnosis of BDC (Fig. 1 ). Data were collected from our endoscopic database and hospital records. Figure 1 shows a flow diagram of the study participants.
Endoscopic Therapy
All EUS-guided procedures were performed with the patient in the lateral or prone position and under conscious sedation with midazolam and fentanyl. A convex array echo endoscope (GF-UCT240-AL5; Olympus Medical Systems, Tokyo, Japan), an US system (ProSound SSD-5000; ALOKA, Tokyo, Japan), and a fluoroscope (CUREVISTA; Hitachi Medical Corp., Tokyo, Japan) were used for all the procedures. All POPFs or dilations of MPD were visible by EUS, and all punctures were performed through the stomach wall.
To perform EUS-TD of POPF, first, an internal fistula was created between the POPF and the stomach by introduction of a 19-gauge needle (Echo Tip Ultra; Cook Endoscopy, Osaka, Japan). Successful POPF access was demonstrated by injection of contrast medium defining a POPF. Next, a 0.035-in. guidewire (Jagwire; Boston Scientific, Tokyo, Japan) was passed through the needle, introduced into the cavity of the POPF, and coiled within the POPF under fluoroscopic guidance. The tract was sequentially dilated with an over-the-wire biliary balloon dilator (6 mm, Hurricane RX; Boston Scientific), a Soehendra biliary dilation catheter (SBDC-6, -7, -8.5; Cook Endoscopy), or a Soehendra stent retriever (7 Fr; Cook Endoscopy). After dilation, a double-pigtail stent (7 Fr, 40 mm; Olympus Medical Systems) was deployed into the fluid-filled space.
For EUS-TD of the dilated MPD, after the pancreatic duct was identified and regional recurrence was confirmed by color-Doppler imaging, the MPD was punctured with a 19-gauge needle (Echo Tip Ultra; Cook Endoscopy), and an internal fistula was created between the MPD and the stomach as the initial step. Successful pancreatic duct access was demonstrated by injection of contrast medium defining a pancreatogram. Next, a 0.035-in. guidewire (Jagwire; Boston Scientific) was passed through the needle and introduced into the cavity of the MPD under fluoroscopic guidance. The tract was sequentially dilated with a Soehendra dilation catheter (SBDC-6; Cook Endoscopy). After dilation, a pancreatic stent (5 Fr, 50 mm; Cook Endoscopy) was deployed into the MPD. Representative images of EUS-TD for POPF associated with the management of case 1 are shown in Fig. 2 .
Percutaneous Drainage of Pancreatic Fistulas
Percutaneous drainage was performed by an interventional radiologist and a surgeon, who punctured the pancreatic fistula by inserting a 0.035-in. guidewire into the fistula space and then placed an indwelling drainage catheter (7.2-Fr strait catheter, O-HIRATA; Medico's Hirata, Osaka, Japan, or 8.5-Fr pigtail catheter; Ultrathane; Cook Endoscopy) under fluoroscopy, US, or CT guidance.
Technical and Clinical Success of EUS-TD and Percutaneous Drainage
Technical success of EUS-TD was defined as the successful placement of a transmural stent or percutaneous catheter into the POPF. Short-term clinical success was defined as a 50% decrease in the POPF or an improvement in the dilated MPD shown on CT images and a decrease in the serum amylase level in the drainage fluid 1 week after treatment. Long-term clinical success was defined as resolution of the POPF or improvement of the dilated MPD shown on CT images 1 month after treatment.
Statistical Analysis
Non-normally distributed variables are expressed as medians (range), and nonparametric tests (Mann-Whitney U test) were used for statistical comparisons. Nominal variables are expressed as frequencies and percentages. The v 2 test with Yates continuity correction for the two-way contingency table was used for statistical comparisons. Fisher's exact test was used in the case of a small expected frequency. Data were considered significant at a P value less than 0.05.
Results
The mean period between the onset of POPF and endoscopic therapy was 7.1 months (range, 1-24 months). The EUS-TD procedure was performed successfully without complications in all six cases (technical success rate, 100%) ( Table 2 ). The size of the fistula decreased remarkably (average reduction rate, 81.2%; range, 46.8-100%) in the five POPF patients. The MPD diameter in case 6 improved after MPD stenting. In all six cases, the serum amylase level was lower after drainage (65 U/l 1 week after drainage vs. 413 U/l before drainage), POPF postoperative pancreatic fistula; EUS-TD endoscopic ultrasound-guided transmural drainage; PC pancreatic carcinoma; PD pancreaticoduodenectomy; PJ pancreatojejunostomy; BDC bile duct carcinoma; HPD hepatopancreaticoduodenectomy; DP distal pancreatectomy; PG pancreatogastrostomy; AC ampullary carcinoma; MPD main pancreatic duct a Case 6 had a dilation of the pancreatic duct by occlusion of pancreatogastrostomy. The value indicates the MPD diameter reflecting decreased pancreatic duct pressure. One patient (case 1) experienced a growth in the cavity by occlusion of the indwelling stent 2 months after the first drainage. This patient underwent a stent exchange using a conventional endoscopic approach.
In the remaining five cases, no recurrences were observed during a mean follow-up period of 7.5 months (range, 1-27 months). Table 3 compares the characteristics of the patient treated by EUS-TD and percutaneous drainage. Both EUS-TD and percutaneous drainage had a final technical success rate of 100%. The short-and longterm clinical success rates of EUS-TD were both 100%, and those of percutaneous drainage were respectively, 61.1 and 83%. These rates did not differ significantly between techniques (short-term clinical success rate, P = 0.091 vs. long-term clinical success rate, P = 0.403). However, the time until clinical success was significantly shorter with EUS-TD (5.8 days) than with percutaneous drainage (30.4 days; P = 0.0013).
Follow-Up Assessment
After discharge, all the patients were followed up by laboratory investigations and CT. Transmural stents were not Fig. 1 Flow diagram of the study participants. AC ampullary carcinoma; BDC bile duct carcinoma; DP distal pancreatectomy; EUS-TD endoscopic ultrasound-guided transmural drainage; GBC gallbladder cancer; HPD hepatopancreaticoduodenectomy; IPMN intraductal papillary mucinous neoplasm; MCN mucinous cystic neoplasm; NET neuroendocrine tumor; PC pancreatic carcinoma; PD pancreaticoduodenectomy; POPF postoperative pancreatic fistula; SPR segmental pancreatic resection retrieved, even after fluid collection was completed. Endoscopic treatment was repeated in the event of stent occlusion. No POPF recurrence was observed during the follow-up time (mean follow-up time, 17.7 months; range, 1-47 months).
Discussion
A pancreatic fistula is as an abnormal communication between the pancreatic duct and another nonepithelized cavity containing pancreas-derived, enzyme-rich fluid
Fig. 2 EUS-TD technique. A CT scan of the abdomen showing a POPF (arrowhead) that developed 24 months after surgical resection. B EUS image of a pancreatic fistula (arrowhead) showing a 71-mm hypoechoic area and introduction of a needle (dotted arrowhead). C-F Fluoroscopic images of EUS-TD. A fine aspiration needle was
used to puncture the fistula under EUS guidance. A guidewire was introduced through the needle and coiled within the fistula cavity under fluoroscopic guidance. Dilation was performed using a dilation catheter. After dilation, a 7-Fr double-pigtail stent was inserted into the fistula POPF postoperative pancreatic fistula; MPD main pancreatic duct a In case 1, a growth developed in the cavity by occlusion of the indwelling stent 2 months after the first drainage, and stent exchange was performed by a conventional endoscopic approach b The value of case 6 indicates the MPD diameter [3, 12] , which occurs mainly after pancreatic resection and trauma. Pancreatic juice may spread throughout the pleura or peritoneum, inducing severe inflammation and autodigestion of peripancreatic and retroperitoneal tissues. A pancreatic pseudocyst, which develops after acute pancreatitis or accompanying chronic pancreatitis, is a localized collection of fluid rich in amylase and other pancreatic enzymes and enclosed by a nonepithelized, hard and thick wall [3, 12] . However, differentiating a POPF from a pancreatic pseudocyst is difficult in some situations. A POPF represents failure of healing or sealing of a pancreatic-enteric anastomosis and a leak of pancreatic juice into the peritoneal or retroperitoneal cavity.
A POPF is treatable by endoscopic, surgical, or percutaneous drainage. Endoscopic transpapillary drainage of the MPD for a pancreatic fistula communicating with the MPD is a relatively easy, well-established first step for patients with POPFs [14, 15] . However, the transpapillary approach occasionally can be difficult due to distortion of the duodenum caused by postoperative changes.
When DP is performed, a transpapillary approach should be considered. However, we did not undertake any endoscopic transpapillary approaches during the period of this retrospective study. Of the six cases, cases 1, 2, 3, 5, and 6 were managed by PD or hepatopancreatoduodenectomy. Although only case 4 was managed by a distal pancretectomy, we performed EUS-TD because POPFs were readily visualized by EUS. The EUS-TD procedure has been performed successfully for POPFs associated with a complete MPD rupture caused by trauma, pancreatoenteric anastomotic breakdown, and occlusion of a pancreatoenteric anastomosis after pancreatic surgery [13, 16, 17] .
As the current report demonstrates, drainage of pancreatic fistulas and MPD by EUS-TD through the gastrointestinal tract was effective and safe in all six cases. The EUS-TD procedure allows access to relatively small and nonbulging pancreatic fistulas and provides visualization of the blood vessels to reduce the risk of bleeding [18, 19] . The EUS-TD procedure also permits internal drainage of pancreatic fluid into the gut, and direct fistula formation between the POPF space and the gut can facilitate POPF closure in one step.
In contrast, percutaneous drainage may lead to the formation of a permanent external fistula in 5-10% of cases [4] . Percutaneous drainage also sometimes requires two or more procedures in a multistep conversion from external to internal drainage and necessitates a longer hospital stay than EUS-TD. Disconnected pancreatic duct syndrome (DPDS) is an anatomic situation defined by a lack of ductal continuity between viable secreting pancreatic tissue and the gastrointestinal tract. The visible upstream pancreas continues secretion without an intact drainage system. The physiologic abnormality of DPDS results in myriad complications including pancreatic pseudocysts, pancreatic ascites, pancreatic fistula, and others [20] .
In our study, we believed that differences in the mechanism of POPF were caused by the methods of surgical anastomosis used. The patients with pancreatojejunostomy (PJ) demonstrated POPFs caused by anastomotic breakdown (cases 1, 2, 3, and 5) or complete rupture (case 4), whereas the patients with pancratogastrostomy experienced stasis of the pancreatic juice caused by occlusion of the anastomosis (case 6).
In our study, EUS-TD to the dilation of the MPD was successful. However, Kahaleh et al. [21] reported that EUS-TD of the dilated MPD failed for 28.5% of the postsurgical patients. Therefore, EUS-guided pancreatic duct drainage remains difficult, especially in the postoperative situation. If recurrence develops after EUS-TD of the dilated MPD, surgery should be considered despite its higher morbidity and mortality rates than found with nonsurgical approaches [22] .
Only one patient (case 1) experienced a relapse of pancreatic fluid collection due to stent occlusion and underwent a second EUS-TD for a stent exchange. Although several reports have indicated the recurrence of pancreatic fluid accumulation after stent removal at the NS not significant, PD pancreaticoduodenectomy, HPD hepatopancreaticoduodenectomy, DP distal pancreatectomy, PJ pancreatojejunostomy, POPF postoperative pancreatic fistula completion of endoscopic transmural drainage, for most patients with a pancreatic fistula who undergo EUS-TD, stent removal is performed routinely within 2 weeks of fistula resolution shown on imaging [6, 23] . The rate of recurrence of pancreatic fistula that requires further endoscopic, surgical, or percutaneous drainage varies from 10 to 30%, and recurrence often occurs within 1 year after treatment [6, 7, 10] . A previous randomized controlled trial regarding stent removal after successful endoscopic transmural drainage of a pancreatic fistula caused by acute pancreatitis or chronic pancreatitis showed that stent retrieval was associated with a higher recurrence rate [24] . In this trial, during a median follow-up period of 14 months, no patients in the persistent stent placement group had POPF recurrence, whereas 5 (38.4%) of the 13 patients in the stent retrieval group experienced POPF recurrence. This result suggests that by maintaining the stent in place, the cystenterostomy tract may remain patent. This patency could be caused by the stent, which acts as a wick and maintains communication between the pancreatic fistula and the stomach.
Prolonged transmural stent placement has been adopted as a strategy to prevent recurrence of POPF [24, 25] . Although Varadarajulu and Wilcox [26] pointed out the risk of stent migration, they reported placement of a permanent indwelling stent by EUS-TD. Furthermore, the appropriate period for stent placement and optimal stent diameter are controversial and yet to be determined. Nevertheless, we consider that a stent remaining in its proper position reduces the recurrence rate.
In our study, the period to clinical success was significantly shorter with EUS-TD than with percutaneous drainage. In two previous studies [27, 28] , a higher failure rate was associated with percutaneous drainage of pancreatic pseudocysts (58%) compared with surgical treatment (7%) [27] , and surgical and endoscopic interventions for pancreatic pseudocysts were as safe and effective as percutaneous drainage [28] . Thus, EUS-TD can be considered a first-line therapy for a pancreatic fistula detectable by EUS when conservative management is ineffective. When EUS-TD cannot be performed, percutaneous drainage or surgical drainage to manage POPF can be considered.
No major complications after EUS-TD were noted in our study. Previous studies have reported complications such as perforation, bleeding, and pancreatitis, although most were not serious [10, 11] . Because major hemorrhage, a rare occurrence during EUS-TD, would require surgery, EUS-TD should be performed only in tertiary care centers [17] .
The limitations of the current study included its retrospective design, the small number of patients studied, and the evaluation of subjects from a single center. Larger studies are needed to understand further the current situation of POPF drainage.
In conclusion, EUS-TD is a technically feasible and apparently safe alternative to percutaneous or surgical drainage for POPF. The EUS-TD procedure can be considered as a first-line therapy for POPFs visible by EUS.
